Porphobilinogen deaminase mutants that cause acute intermittent porphyria have been investigated as recombinant proteins expressed in Escherichia coli, yielding important insight into the mechanism of dipyrromethane cofactor assembly and tetrapyrrole chain polymerization. A mutation that affects a key catalytic residue, D99G, results in an inactive holo-protein that exists as a complex with two substrate molecules covalently bound to the dipyrromethane cofactor arising from the reaction between the apo-protein and pre-uroporphyrinogen. The R149Q mutant is also devoid of catalytic activity but the mutant protein is unable to assemble the dipyrromethane cofactor from pre-uroporphyrinogen and persists as an unstable, heat-labile apo-protein. The mutant, R173Q, has very low activity and, like R149Q, also exhibits largely as an apo-protein. The inability to reconstitute either R149Q or R173Q with exogenous pre-uroporphyrinogen confirms the importance of these two arginine residues for dipyrromethane cofactor assembly. In contrast, the mutant R167Q exists as a holo-enzyme but the catalytic cycle is severely compromised, leading to the accumulation of stable enzyme-substrate intermediates from the catalytic cycle.
Introduction
Porphobilinogen deaminase (also named hydroxymethylbilane synthase; EC 4.3.1.8), the third enzyme of the haembiosynthesis pathway, catalyses a novel transformation in which four molecules of the pyrrole, porphobilinogen, are polymerized to give a linear tetrapyrrole called preuroporphyrinogen, as shown in Scheme 1 (for a review see [1] ). Pre-uroporphyrinogen is subsequently cyclized, with rearrangement, to form uroporphyrinogen III in a reaction catalysed by uroporphyrinogen III synthase. As a 1-hydroxymethylbilane, pre-uroporphyrinogen is extremely unstable, cyclizing in a non-enzymic reaction to give uroporphyrinogen I with a half-life of 4 min at pH 8 and 37
• C (see Scheme 1) . In humans, under normal circumstances, because the activity of porphobilinogen deaminase is far lower than that of uroporphyrinogen III synthase, preuroporphyrinogen never accumulates in vivo and porphobilinogen is converted by the two enzymes exclusively into uroporphyrinogen III.
The X-ray structure of porphobilinogen deaminase was solved in our laboratories over a decade ago [2] and this has provided extensive insight into how the enzyme catalyses what is a highly complex polymerization reaction. The key to the reaction is the presence, at the active site, of the dipyrromethane cofactor [3] , an active-site group unique to all porphobilinogen deaminases. The dipyrromethane is elongated by the stepwise addition of four molecules of porphobilinogen through intermediates ES, ES 2 and ES 3 to give an enzyme bound 'hexapyrrole', ES 4 . The enzymic product, pre-uroporphyrinogen, is released from ES 4 by a hydrolytic reaction that regenerates the holo-deaminase with the cofactor still resident at the active site (Scheme 2). The dipyrromethane cofactor is not assembled from porphobilinogen but arises from pre-uroporphyrinogen in a fascinating reaction involving C-alkylation of Cys-261 of the apo-deaminase by reaction with the 1-hydroxymethyl group of pre-uroporphyrinogen. This generates ES 2 directly [4] .
A large number of human mutations have been identified in porphobilinogen deaminase that lead to the inherited disease acute intermittent porphyria (AIP). AIP is characterized by acute attacks, typically with severe abdominal pain and often accompanied by neurological symptoms including muscular weakness and psychotic episodes [5] . In all cases, acute attacks are accompanied by raised urinary levels of the haem-biosynthesis intermediates 5-aminolaevulinic acid and porphobilinogen. Despite extensive research, no direct link between the raised levels of 5-aminolaevulinic acid and porphobilinogen and the acute symptoms has been convincingly made, although there is little doubt that such a link exists. One of the most perplexing aspects of AIP 
Scheme 2 The catalytic cycle of porphobilingen deaminase
The reaction involves the elongation of the enzyme-bound dipyrromethane cofactor by the stepwise addition of four molecules of the substrate porphobilinogen through ES, ES 2 and ES 3 to give ES 4 , an enzyme-bound 'hexapyrrole'.
The hydroxymethylbilane product pre-uroporphyrinogen is released from ES 4 by hydrolysis, regenerating the unchanged dipyrromethane cofactor. The dipyrromethane cofactor arises initially from the reaction of Cys-261 of the deaminase apo-enzyme with pre-uroporphyrinogen, and the resulting ES 2 complex then enters the catalytic cycle. The Figure 1 legend gives the structures of A and P.
is the low penetrance of the disease and the lack of any obvious relationship between genotype and phenotype. Thus heterozygotes, despite having only 50% of the normal level of porphobilinogen deaminase, may live their entire life without suffering an acute attack. Other carriers of the defect, however, may suffer debilitating and even life-threatening acute attacks at frequent intervals. Mutations in porphobilinogen deaminase come under several categories with defects in mRNA splicing and exon deletions causing particularly catastrophic effects on the formation of the porphobilinogen deaminase protein. However, it is the investigation of the missense mutations and their molecular consequences that has provided the most valuable insight into structure/function relationships of the enzyme [6] .
Mutations may be placed into several broad classes. There are those that lead to a truncated protein, such as W198X, a mutation exceptionally common in Sweden [7] . There are a number of mutations in the hydrophobic core of the enzyme that are likely to compromise normal protein folding or that result in an unstable protein [8] . Some mutations, like R149Q [9] and R173Q [10] , are thought to result in apoproteins. Other mutations, at the active site, are expected to prevent normal substrate binding, such as R26H [11] . Mutations, like R167Q [9] , are thought to compromise the polypyrrole elongation mechanism to form the tetrapyrrole, resulting in the accumulation of stable enzyme-intermediate complexes. One mutation [12] involves a key catalytic group, D99G, and leads to the formation of an enzyme-intermediate complex that, nevertheless, has no catalytic activity. Some of the mutants result in a cross-reacting immunogenic material (CRIM)-negative status due to the instability of the protein.
This paper deals with four natural human mutant porphobilinogen deaminases, D99G, R149Q, R167Q and R173Q. All four mutants have been expressed in vitro using a recombinant Escherichia coli expression system. The study of these mutants has provided important information about apo-deaminase stability, dipyrromethane cofactor assembly, cofactor binding groups and the mechanism of pyrrole elongation during the catalytic cycle.
Materials and methods
Human ubiquitous porphobilinogen deaminase cDNA was generously provided by Professor B. Grandchamp (Hôpital Bichat, Paris, France) and, using PCR with the appropriate primers, was modified for ligation as an NdeI/BamHI fragment into pT7-7 [13] . Transformation of recombinant plasmids into E. coli BL21 was achieved using standard procedures. Recombinant human ubiquitous porphobilinogen deaminase expression was induced with isopropyl β-D-thiogalactoside after the bacterial culture had reached an absorbance of 0.8 and growth was extended for a further 4 h before harvesting the cells.
The human porphobilinogen deaminase was purified as follows. Bacterial pellets were initially sonicated under nitrogen gas and extracts were subjected to heat treatment at 60
• C for 3 min followed by ultracentrifugation to remove cell debris. The enzyme was chromatographed on DEAE Sephacel in 20 mM Tris/HCl buffer, pH 8.2, and eluted with a gradient of KCl extending from 0 to 100 mM. The purified wild-type enzyme had a specific activity of 2.1 µmol of uroporphyrin/h per mg. Purifications of unstable mutant apo-deaminase proteins were carried out as described previously for the E. coli deaminase [4] .
Human porphobilinogen deaminase was assayed by incubating enzyme (0. [3, 14] .
Results and discussion

Human porphobilinogen deaminase D99G mutant
In human porphobilinogen deaminase, Asp-99 is a key catalytic residue, being involved in each of the four deamination and condensation reactions to form ES 4 , as well as in the hydrolytic reaction to release the product preuroporphyrinogen [1] . This mutant deaminase expressed normally and was stable to the heat-treatment stage used in the purification procedure. Assay of the purified protein with porphobilinogen indicated that the D99G mutant was totally devoid of any deaminase activity and SDS/PAGE revealed that the protein had the expected molecular mass of 44 kDa and migrated as a single band. Non-denaturing gel electrophoresis, however, showed that the mutant protein migrated substantially faster than native deaminase with a mobility similar to that expected for an ES 2 enzymeintermediate complex (see Scheme 2) . Whereas reaction of the normal porphobilinogen deaminase with Ehrlich's reagent showed an initial purple colour that faded to an orange colour over a period of 10 min ( Figure 1A) , reaction of the D99G protein gave an immediate orange colour reaction reminiscent of a tetrapyrrole (bilane) with no further change over 10 min ( Figure 1B) .
These findings suggest that the human D99G mutation results in an inactive holo-protein that is equivalent to the native enzyme-intermediate complex, ES 2 . Thus, despite the fact the enzyme is inactive, due to the loss of the catalytic Asp-99, pre-uroporphyrinogen can still bind to the active site and alkylate Cys-261 in the normal way. Once preuroporphyrinogen has reacted, the absence of the catalytic aspartate prevents the addition of any further substrates and also prevents the holo-protein from participating in the well-established 'reverse' reactions with NH 3 or hydroxylamine (or water). The mutant holo-protein is thus completely blocked from further transformation. This mutation highlights the fact that, despite being essential for catalysis, Asp-99 is not essential for the binding or reaction of pre-uroporphyrinogen with the deaminase apo-enzyme during cofactor assembly. A related mutation, D84A, in the porphobilinogen deaminase from E. coli shows similar properties to the D99G human mutant in that it also appears to exist as an inactive ES 2 complex [15] .
Human porphobilinogen deaminase R149Q and R173Q mutants
Both mutations were initially characterized in patients with acute intermittent porphyria [9, 10] and affect two of the invariant arginine residues in the active-site cleft. Arg-149 makes contacts with the dipyrromethane cofactor where it interacts with the acetic acid side chains of the C-1 ring. It also contributes to a complex hydrogen-bonding network involving Asp-124 and Lys-98. Arg-173 also makes interactions with the cofactor through the propionic acid side chain of ring C-1 and is implicated in binding the propionic acid side chain of the substrate porphobilinogen [2] .
Both recombinant human mutants expressed normally and SDS/PAGE of crude extracts showed a band at 44 kDa for each. Neither protein exhibited any catalytic activity in crude extracts and, during the heat treatment used in the purification, the deaminase band was lost, suggesting that the mutant proteins existed as unstable apo-enzymes. Further investigation of crude extracts revealed that the R149Q mutant is Ehrlich's negative, but that R173Q was weakly Ehrlich's positive. Both proteins were purified to homogeneity by a modified procedure using an affinity column containing Mimetic Orange [4] . This matrix binds to the apo-deaminase but not to the holo-deaminase. Following purification, attempts to reconstitute the R149Q and R173Q apo-proteins with the cofactor precursor, preuroporphyrinogen, were made. The R149Q mutant failed to form any holo-protein; however, the R173Q mutant showed a very weak Ehrlich's reaction after treatment with pre-uroporphyrinogen. Non-denaturing PAGE (results not shown) revealed that both mutant proteins migrated as 'smears' on the protein gel, indicating their existence as incompletely folded apo-enzymes [4] .
The conclusions from these investigations highlight the importance of Arg-149 and Arg-173 in the initial recognition and binding of pre-uroporphyrinogen by the apo-deaminase. For pre-uroporphyrinogen to react with Cys-261, the rings destined to be C-1 and C-2 in the dipyrromethane cofactor would need to bind to the protein in such a way as to place the hydroxymethyl group of pre-uroporphyrinogen close to Cys-261. These mutations clearly prevent the preuroporphyrinogen from docking correctly and suggest that both residues are essential for the apo-protein → holo-protein transformation. Broadly comparable results were obtained with equivalent mutations of Arg-131 and Arg-155 in the E. coli porphobilinogen deaminase [16] . The former is an inactive, heat-labile, apo-enzyme whereas the latter is a severely crippled enzyme with less than 1% of the activity of wild-type deaminase. These results contrast strongly with those for D99G in which pre-uroporphyrinogen can dock and react with the apo-deaminase but the resulting holoprotein cannot participate in catalysis.
Human porphobilinogen deaminase R167Q mutant
The final investigation involved R167Q, one of the first human porphobilinogen deaminase mutations to be characterized [9] . Arg-167 is located in the active-site cleft and is ideally placed to interact with the acetic acid side chain of the substrate, porphobilinogen. The purified R167Q mutant deaminase appeared normal in all aspects except that it exhibited less than 10% of the activity of the native enzyme when incubated with porphobilinogen and migrated as a less basic pair of protein species on non-denaturing PAGE analysis (Figure 2) . Incubation of the R167Q mutant with porphobilinogen, as with native enzyme, revealed the immediate formation of enzyme-intermediate complexes (see Figure 2, lanes 3 and 4) . However, the complexes of the R167Q mutant were exceptionally stable and persisted for over 30 min (see Figure 2 , lane 8) whereas those formed by the native enzyme rapidly turned over to product and reformed the original enzyme (Figure 2, lane 7) . 
Conclusions
The study of four naturally occuring human mutations of recombinant ubiquitous porphobilinogen deaminase has revealed important aspects about the process by which the dipyrromethane cofactor is assembled. One of the mutants, D99G, gives rise to a totally inactive enzyme that, despite the absence of an essential catalytic group, harbours the dipyrromethane cofactor, albeit in the form of a stable enzyme-intermediate complex ES 2 . Two other mutants, R149Q and R173Q, result in unstable, inactive apoproteins, despite the fact that both contain the catalytic Asp-99 and the residue essential for cofactor attachment, Cys-261. These experiments highlight the importance of Arg-149 and Arg-173 for the initial binding and positioning of preuroporphyrinogen within the apo-deaminase active site. The last mutant investigated, R167Q, is particularly interesting because it provides evidence that Arg-167 is important for controlling the elongation process at all stages of tetrapyrrole formation. Thus the R167Q mutant appears to be capable of catalysing the bond-forming and -breaking events but the mechanism of translocation of the growing polypyrrole chain within the active-site cleft is severely compromised. 
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